Evidence map›Paper›PMID 28413641›Full record

ArticleBiomedical reports2017

Serum miR-20a is a promising biomarker for gastric cancer.

Ruirui Yang, Yun Fu, Ying Zeng, Mengqin Xiang, Yufang Yin, Li Li, Haifan Xu, Jing Zhong, Xi Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Association of miR-338-3p with survival outcomes in gastric cancer patients who received peri-operative blood transfusion.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  8. Review
  9. Circ-SHPRH in human cancers: a systematic review and meta-analysis.Frontiers in cell and developmental biology · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. The Emerging Role of Circ-SHPRH in Cancer.OncoTargets and therapy · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Function and mechanisms of microRNA-20a in colorectal cancer.Experimental and therapeutic medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruirui YangHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, University of South China, Hengyang, Hunan 421001, P.R. China.
Yun FuHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, University of South China, Hengyang, Hunan 421001, P.R. China.
Ying ZengSchool of Nursing, University of South China, Hengyang, Hunan 421001, P.R. China.
Mengqin XiangHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, University of South China, Hengyang, Hunan 421001, P.R. China.
Yufang YinDepartment of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL 62702, USA.
Li LiHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, University of South China, Hengyang, Hunan 421001, P.R. China.
Haifan XuDepartment of Surgical Oncology, The First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
Jing ZhongInstitute of Clinical Medicine, The First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
Xi ZengHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, University of South China, Hengyang, Hunan 421001, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is a common type of cancer, particularly in China. Numerous studies have demonstrated that circulating microRNAs (miRNAs) have potential applications as noninvasive biomarkers for cancer diagnosis and prognosis. Microarray-based serum miRNA profiling was performed on the serum of 12 paired pre- and post-operative GC patients to screen differentially expressed serum miRNAs. Twelve different serum miRNAs between pre- and post-operative GC patients were identified. Those miRNAs were verified by real-time quantitative polymerase chain reaction in 110 paired pre- and post-operative serum samples from 55 GC patients. miR-20a was confirmed and demonstrated potential as a GC-associated biomarker. Furthermore, the levels of serum miR-20a were significantly different between GC, nasopharyngeal cancer, colorectal carcinoma, breast cancer and non-cancerous controls. In addition, it was found that serum miR-20a levels correlated with age, tumor stage, differentiated degree and lymph node metastasis in GC. Survival analysis indicated that GC patients with elevated levels of serum miR-20a had poor survival. Thus, serum miR-20a may serve as a molecular marker for diagnosis, evaluating therapeutic efficacy and prognosis, as well as monitoring recurrence in GC patients.

Indexed as

biomarkergastric cancermiR-20aserum

Identifiers

PMID28413641
PMCPMC5374949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.